SGLT2 Inhibition in Combination With Diuretics in Heart Failure

Inclusion Criteria: * Diagnosis of NYHA Functional class II-III HF with prior echocardiographic evidence of LVSD. * On stable doses of furosemide, or alternative loop diuretic for at least one month. * Stable Type 2 Diabetes (HbA1c, in the last 3 months, of 6.5% ≤ and ≤10.0%) * eGFR ≥ 45 ml/min. * Have stable HF symptoms for at least three months prior to consent * On stable HF therapy for at least three months prior to consent * Have not been hospitalised for HF for at least three months prior to consent. * Women of childbearing potential must agree to take precautions to avoid pregnancy throughout the trial and for 4 weeks after intake of the last dose. Exclusion Criteria: * A diagnosis of chronic liver disease and/or liver enzymes that are twice the upper limit of normal * Systolic BP of \<95mmHg at screening visit. * Participants on thiazide diuretics. * Participants receiving renal dialysis * Participants who have previously had an episode of diabetic ketoacidosis. * Participants with type 1 diabetes mellitus * Malignancy (receiving active treatment) or other life threatening disease. * Pregnant or lactating women * Participants with difficulty in micturition e.g. severe prostate enlargement * Allergy to any SGLT2 inhibitor or lactose or galactose intolerance * Past or current treatment with any SGLT2 inhibitor * Participants who have participated in any other clinical interventional trial of an investigational medicinal product within 30 days. * Participants who are …